



---

## STRESSGEN INITIATES PHASE II GENITAL WARTS TRIAL

### *Trial Expands Broad-Spectrum Activity of HspE7 in HPV-Related Diseases*

FOR IMMEDIATE RELEASE

January 9, 2001

**Victoria, British Columbia** – Stressgen Biotechnologies Corp. (TSE: SSB) announced today that it has initiated a Phase II clinical trial to investigate HspE7 as a novel immunotherapeutic for genital warts caused by the human papillomavirus (HPV). This double-blind placebo-controlled study will involve 52 patients at multiple study centers in the United States. Effectiveness will be assessed as regression of warts by standardized clinical criteria. Stressgen also has an active Phase III HspE7 study for HPV-related anal dysplasia and two Phase II studies in women with HPV-related cervical dysplasia and cervical cancer.

HPV is one of the most common sexually transmitted diseases (STDs) in the world. There are 5.5 million new cases of genital HPV infection diagnosed per year in the US alone, of which over 1 million represent cases of genital warts. In addition to warts, genital HPV infection can cause a variety of precancerous conditions, including anal and cervical dysplasia. Left undiagnosed, or untreated, dysplastic cells can become cancerous. HPV is also responsible for laryngeal warts as well as some head and neck cancers.

“The initiation of this trial represents the achievement of another milestone for Stressgen,” said Daniel Kopolinski, President and CEO of Stressgen Biotechnologies. “Genital warts in conjunction with high-grade cervical and anal dysplasia represent over 2.2 million cases of the genital HPV infections each year in the US. It is clear that these diseases are a major public health issue and better treatments need to be developed. We believe that HspE7 may offer a novel therapeutic solution.”

Stressgen Biotechnologies is a biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. Stressgen’s lead product HspE7 targets a variety of HPV-related diseases. Stressgen has also initiated research studies to evaluate the technology in the treatment of asthma and allergy as well as Hepatitis. Stressgen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.

-30-

Contact: Elisabeth Whiting, Director, Corporate Communications & Investor Relations  
StressgenBiotechnologies, 350-4243 Glanford Ave. Victoria, BC V8Z 4B9  
Tel. 250-744-2811 Fax 250-744-3331 Email. [ewhiting@stressgen.com](mailto:ewhiting@stressgen.com)

*This foregoing press release may contain statements that are not based on historical fact, including, without limitation, statements containing the words “believes”, “may”, “will”, “intends”, “plans”, “expects” and words of similar import. Such statements may constitute “forward-looking” statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. A number of factors could cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements implied by such statements. Such factors include, but are not limited to, those with respect to the timing of regulatory submissions and approvals, the ability of the Company to continue to develop its products (including HspE7), the Company’s ability to maintain or expand its intellectual property position, the timing and success of planned or existing clinical trials and anticipated levels of revenues and expenses and others, all as described Company’s Registration Statement on Form F-10 and other filings with the U.S. Securities and Exchange Commission.*

# # #